Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Casma Therapeutics

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

Moderna receives FDA emergency authorisation for its COVID-19 vaccine

Moderna's vaccine is the second to receive FDA approval, following approval of Pfizer/BioNTech’s BNT162b2 vaccine

- PMLiVE

Moderna scores FDA panel backing for mRNA-based COVID-19 vaccine

EMA also brings forward review meeting of vaccine

- PMLiVE

FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine

Briefing document published ahead of advisory committee meeting

- PMLiVE

Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021

85 million to 100 million doses will be available in the US

- PMLiVE

Moderna eyes COVID-19 vaccine approval in the US and the EU

Updated analysis demonstrates efficacy of 94.1%

- PMLiVE

Moderna and UK sign agreement for additional doses of COVID-19 vaccine

The UK has secured another two million doses on top of previously agreed five million doses

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

- PMLiVE

Moderna’s COVID-19 vaccine is 94.5% effective, initial data suggests

The UK government has secured access to five million doses of the vaccine

- PMLiVE

Moderna preparing for interim analysis of late-stage COVID-19 vaccine data

The company has accrued enough COVID-19 cases in the trial for interim analysis

- PMLiVE

Moderna posts encouraging early data for personalised cancer vaccine

Vaccine tested alongside Merck's Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links